Armata Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Armata Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($26.68M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($16.30M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($6.53M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($5.48M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | $8.99M | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($25.02M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($31.16M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($3.55M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($14.49M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($8.61M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($9.22M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($8.77M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($5.42M) | Nov 9, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($6.19M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($5.50M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($5.77M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($4.71M) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($5.08M) | May 13, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($6.96M) | Nov 12, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($4.20M) | Aug 13, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($7.78M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($6.84M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($8.19M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($9.76M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($11.91M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($10.23M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($10.34M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($9.63M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($11.35M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($8.62M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($9.22M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($8.78M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($6.14M) | Nov 9, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($6.20M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($5.44M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($5.62M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($4.59M) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($4.92M) | May 13, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($6.78M) | Nov 12, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($5.16M) | Aug 13, 2020 |